Entrada Therapeutics, Inc. TRDA R2KR3KPHARMA
Company Overview
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.21.
Recent Developments
- Dec 2025 Revenue of $25.42M (-87.9% YoY); net profit $-143.75M.
- Trailing 12 Months Year-on-year growth — revenue -53.9%, earnings -319.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -55.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -55.61% |
| 1 Year: | -53.90% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -319.04% |
Stock Price Performance
| 1 Year: | +34.02% |
| 6 Months: | -43.32% |
| 3 Months: | +11.93% |
| 1 Month: | +3.78% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)49.25 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -55.6% CAGR over 5 years.
- Trading 55.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TRDA Entrada Therapeutics, Inc. R2KR3KPHARMA | 7.13 | -1.80 | $277.62M | 0.00% | -44.74% | -54.10% | -55.61% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 0 | 25.26M | 18.17M | 43.73M | 59.12M | 94.69M | 19.57M | 20.56M | 1.95M | 1.61M | 875.00K | 898.00K |
| Operating Income | - | - | -6.97M | -8.39M | -9.91M | -14.36M | -22.15M | -23.58M | -25.94M | -5.78M | -16.30M | 14.01M | 21.11M | 53.42M | -21.66M | -21.79M | -46.85M | -47.05M | -42.30M | -44.96M |
| Net Income | -4.69M | -6.17M | -6.99M | -8.38M | -9.90M | -14.43M | -21.67M | -23.18M | -25.14M | -6.67M | -25.93M | 35.46M | 23.50M | 55.03M | -14.03M | -17.35M | -43.10M | -44.13M | -39.72M | -42.76M |
| Diluted EPS | - | - | -6.13 | -6.67 | -7.56 | -9.78 | -0.69 | -0.74 | -0.80 | -0.21 | -0.78 | 1.02 | 0.68 | 1.55 | -0.35 | -0.42 | -1.04 | -1.06 | -0.95 | -1.01 |
| R&D Expense | - | - | 5.70M | 6.22M | 6.83M | 10.51M | 15.72M | 16.25M | 18.96M | 23.10M | 26.30M | 22.19M | 28.61M | 32.03M | 31.26M | 32.07M | 37.88M | 38.36M | 33.05M | 35.37M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 129.01M | 210.78M | 25.42M |
| Operating Income | -26.67M | -51.13M | -97.25M | -3.16M | 47.01M | -157.90M |
| Net Income | -26.52M | -51.16M | -94.62M | -6.68M | 65.63M | -143.75M |
| Diluted EPS | -24.00 | -8.16 | -3.02 | -0.20 | 1.68 | -3.47 |
| R&D Expense | 21.10M | 35.93M | 66.61M | 99.88M | 125.31M | 142.27M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 43.53M | 305.83M | 252.06M | 469.19M | 526.32M | 377.38M |
| Total Equity | -15.52M | -41.49M | 298.72M | 212.55M | 242.36M | 428.68M | 306.13M |
| Cash & Equivalents | - | 39.05M | 291.06M | 45.16M | 67.60M | 101.21M | 90.39M |
| Total Liabilities | - | 3.36M | 7.12M | 39.50M | 226.83M | 97.64M | 71.25M |
| Current Liabilities | - | 3.36M | 6.72M | 21.97M | 158.80M | 39.48M | 24.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -25.57M | -50.86M | -93.79M | 139.80M | -41.56M | -128.51M |
| Investing Cash Flow | -2.32M | -4.58M | -148.65M | -138.40M | -27.80M | 116.81M |
| Financing Cash Flow | 50.09M | 307.46M | 479.00K | 21.04M | 102.96M | 887.00K |
| Capital Expenditure | -2.32M | -4.58M | -2.89M | -5.61M | -3.16M | -1.04M |
| Free Cash Flow | -27.89M | -55.44M | -96.67M | 134.19M | -44.72M | -129.55M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -2.5% | 22.3% | -621.1% |
| Net Margin % | - | - | - | -5.2% | 31.1% | -565.5% |
| ROE % | 63.9% | -17.1% | -44.5% | -2.8% | 15.3% | -47.0% |
| ROCE % | -66.4% | -17.1% | -42.3% | -1.0% | 9.7% | -44.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Baker Bros. Advisors, LP | 13.03% | 5.07M | $35.51M |
| 2 | 5AM Venture Management, LLC | 10.42% | 4.06M | $28.39M |
| 3 | Blackrock Inc. | 6.63% | 2.58M | $18.08M |
| 4 | Merck & Co., Inc. | 4.47% | 1.74M | $12.18M |
| 5 | Vanguard Capital Management LLC | 3.26% | 1.27M | $8.89M |
| 6 | MPM Bioimpact LLC | 3.22% | 1.25M | $8.77M |
| 7 | TCG Crossover Management, LLC | 2.72% | 1.06M | $7.42M |
| 8 | Wellington Management Group, LLP | 2.45% | 954.42K | $6.68M |
| 9 | StepStone Group LP | 1.96% | 761.28K | $5.33M |
| 10 | Millennium Management Llc | 1.96% | 763.96K | $5.35M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TRDA
Institutional holder sells Entrada (NASDAQ: TRDA) shares over three days - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOTkh5bHU0VWkwQTJRTkRvS1FoSE1IX1R1WHUzbUZZdkgyMHBQSFZ2OHNGZWpLN2dFMi12X2JnX2xRV0JIMFlEc2NvNjh6cnZCNkRnb1h2SGVIbTdLbGlsQmtQWnhOblFRTzl2UkRJc2lqaFpic0RGVFlkdDYtVkdTeTNrTkRZc3MtdXczSU…
Insider Sale: 10% owner at $TRDA Sells 3,733 Shares - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQNDhZUUlfTEtITGhQbUlCVC1aZUZDeE5WdjZ6Z0dOaUpKU3FIbk1nMTFQVFZBM3doQ1lZaWNSUlZGdVQ2MGRqRDZoMDU0ZmRQSVZkZjlYM1FyZmpZaWVtY2JTZkNxVmdXNVJQVkxDS2xLQkhoVEl3cTE4UW4xclNfYkFBTnlDYW5SMUx4eG…
TRDA - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9VR3NCODN0bVVTdlM0dENRRWxzdFc1WTlkOFNScnE2WnRLYVExcF9PT0MwSnRMdEZYN0M2Z2hiVHRIX0V4WUE?oc=5" target="_blank">TRDA</a> <font color="#6f6f6f">Finviz</font>…
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQaUJlNW1wYi1SWWVXZFJaSFBUXzJpRjRMZjZpOGFaV1RKeUdfeFFadHhidkJwV2pHN0VYLW5nbmFGVFFZeUVHTjhfcGZFemVtam9mYUtXRmFTYklnV0ZhYjctdVdFZU1hWlJhQUJIODZlYjBpTEVUaldYay1jVTJRTjBwSVNnc2gzQm1IVj…
MPM funds sell Entrada (TRDA) shares without 10b5-1 plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOZlFpbWZhUDRzT21jamZWa2o1TXA0MzZnSGp4RDhnMTJvNlE2NzZPT2x1T3IxaTVfc2huT1FuT083dmFjem40ZFdGLWpubGtBVEVQdTdXMndzVFJGZmpyMU5yYU1IX1NtWDZLZ1RzWENIUGxZVG1EU2FvZzl6WlJBX0FXQ1dSUzItV2JXZU…
TRDA Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBsemFYaVhzRF94MzRCUnZ6VnFuSWhBOFl5VmRWT1cxeS1PdUpOcnFKekxPMDVCYjlwOVlCNFJJRnZvQTIySFNCSllzSlZuS1ZjSDY3MWJUdEYzVlQwT0xsTkR0cWtmaXRqZGdxaHZtX3lRSm5aeVdSSmVR?oc=5" target="_blank">TRD…
TRDA — Frequently Asked Questions
What is the current share price of Entrada Therapeutics, Inc. (TRDA)?
As of 2026-09-07 16:24 PDT, Entrada Therapeutics, Inc. (TRDA) trades at $7.13 on NasdaqGM. Its 52-week range is $5.06 to $16.03.
What is the market capitalisation of TRDA?
Entrada Therapeutics, Inc. (TRDA) has a market capitalisation of $277.62M on NasdaqGM.
What is the P/E ratio of TRDA?
TRDA trades at a trailing price-to-earnings (P/E) ratio of -1.80. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.91.
What is the return on equity (ROE) of TRDA?
TRDA has a return on equity (ROE) of -54.10%. Its return on capital employed (ROCE) is -44.74%.
Is TRDA a good stock to buy?
This page provides a data-driven analysis of Entrada Therapeutics, Inc. (TRDA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.